Search
Elebsiran
go.drugbank.com/drugs/DB19018InvestigationalElebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).
Olorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Categories: Experimental Unapproved Treatments for COVID-19Sarconeos
go.drugbank.com/drugs/DB16457InvestigationalSarconeos is an activator of the MAS receptor.
Categories: Experimental Unapproved Treatments for COVID-19Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.
Categories: Experimental Unapproved Treatments for COVID-19STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Categories: Experimental Unapproved Treatments for COVID-19STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19TY027
go.drugbank.com/drugs/DB16500InvestigationalCategories: Experimental Unapproved Treatments for COVID-19BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Categories: Experimental Unapproved Treatments for COVID-19Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.